Although CDK4/6 inhibitors have had great value in the treatment of metastatic HR+/HER2− breast cancer, a better understanding of their value is needed in early stage HR+/HER2− breast cancer for the following reasons. The gene discussed is CDK4; the disease is breast carcinoma.